Kanungo Financiers Merger & Restructuring Worth ₹81.32 Cr

Kanungo Financiers Q2 FY27 Results: Net Profit ₹0 Cr

Kanungo Financiers reported unaudited Q2/H1 FY27 results with zero revenue from operations and a Q2 loss of Rs.3.98 lakhs. Other income fell sharply year-on-year, from Rs.45.46 lakhs to Rs.8.47 lakhs.

Key figure

Net profit ₹0 Cr

Kanungo Financiers Board Meeting Date

Kanungo Financiers will hold a board meeting on 3 November 2026 to consider unaudited results for the quarter and half year ended 30 September 2026. The filing is a Regulation 29 prior intimation.

Kanungo Financiers Other Announcement

The company filed a Regulation 74(5) compliance certificate for the quarter ended September 30, 2026, confirming the dematerialization of shares.

Kanungo Financiers Annual General Meeting

Kanungo Financiers Limited held its Annual General Meeting on September 29, 2026. Shareholders transacted agenda items including financial statement adoption and director appointments.

Kanungo Financiers Board Meeting Outcome

Kanungo Financiers Limited approved its Q1 financial results and accepted the resignation of its statutory auditor, H S K & Co LLP.

Kanungo Financiers Annual General Meeting

Kanungo Financiers Limited has announced a book closure period from September 23, 2026, to September 29, 2026, for its upcoming Annual General Meeting.

Narayana Hrudayalaya Merger & Restructuring

Narayana Hrudayalaya's NCLT Bengaluru bench sanctioned the demerger of clinical services from its subsidiary NH Integrated Care. Order uploaded today; effectiveness awaits certified copy filings.

Abans Enterprises Merger & Restructuring

Abans Enterprises' board approved voluntary liquidation of wholly owned subsidiary AGJT, subject to shareholder approval. Completion is expected within one year.

Execution

Expected within one year, subject to approvals and statutory formalities

Max Estates Merger & Restructuring Worth ₹0.01 Cr

Max Estates will subscribe to 10,000 shares worth ₹1 lakh in a yet-to-be-incorporated real estate company. The entity awaits Ministry of Corporate Affairs approval.

Value

₹0.01 Cr

Aurobindo Pharma Merger & Restructuring Worth ₹29 Cr

Aurobindo Pharma approved transferring 100% of Auro Pharma LLC, Russia, between wholly owned subsidiaries. Cash consideration is about INR 29 crore, subject to adjustments.

Value

₹29.00 Cr

Execution

60-90 days

Choice International Merger & Restructuring Worth ₹1.27 Cr

Choice International sold a unit or subsidiary to Arrowbridge Trade for Rs.1.275 Crore in cash. The buyer is unrelated and the deal is at arm's length.

Value

₹1.27 Cr

Shringar House of Mangalsutra Merger & Restructuring Worth ₹5 Cr

Shringar House of Mangalsutra will incorporate a wholly owned jewellery subsidiary, subscribing Rs 5 Crore in cash. The subsidiary becomes a related party once formed.

Value

₹5.00 Cr